Search Results
Targeting mutated MYD88 pro-survival signaling in B-cell malignancies
Our laboratory and those of others discovered highly recurring mutations in the gene MYD88 which are found in patients with various B-cell cancers including Waldenstrom’s Macroglobulinemia (95-97%), ABC Subtype of Diffuse B-cell Lymphoma (30-40%), Primary Central Nervous Lymphoma (80%), Marginal Zone Lymphoma (10%) and Chronic Lymphocytic Leukemia (5-10%).KT1, a novel NK trispecific antibody for the treatment of AML and MDS
New treatments for AML and MDS are urgently needed. We have developed and performed preliminary testing of a novel, patent-protected, trispecific NK cell engager named KT1 which targets AML blasts and leukemia stem cells (LSCs) expressing CD33 and CD123 for elimination by effector cells that express CD16a/b.Financial and Legal
Balancing WorkThe many responsibilities of caring for someone often leads to job conflicts. Work is a financial necessity and a major source of personal satisfaction, but for many caregivers, it is often difficult to balance the twin responsibilities of caregiving and working. Each caregiver’s working conditions are different. Talk to your supervisor and look in the employee handbook or other human resources publications to learn about your company’s policy on caregivers.
Epigenetic Mechanisms and Targeting in Hematological Malignancy
Blood cancers can be caused by aberrant regulation of genes that control cell growth and development. The root cause of this problem may be the presence of mutant regulator proteins in the cell and abnormal switching on or off of target genes. Our SCOR studies the molecular basis of this gene deregulation using cell cultured in the laboratory, in human specimen and animal models.Understanding Blood Cancers and Treatment Options
Leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the bone marrow, blood cells, lymph nodes and other parts of the lymphatic system. See the Disease Information pages to learn more about the different types of blood cancer.
Nutrition
Food provides valuable nutrients for cancer patients. Eating well during cancer treatment helps to speed recovery, ease side effects, and keep the treatment plan running smoothly.
Related Diseases
Chronic lymphocytic leukemia (CLL) shares some similar features and symptoms with other closely related types of leukemia.
Izabella
When I was twelve years old, I was diagnosed with a very rare type of leukemia found in children. I was life-flighted, had various treatments and procedures, and even had four blood transfusions. As incredibly shocking and terrifying as it all was, I pulled through in only a week of treatment. My type of leukemia is called chronic myeloid leukemia (CML). This leukemia is something that will be a part of me forever. Even still, I take a daily oral chemotherapy pill. Despite all of this, I maintain my path in life and will not let anything stop me.
Sherri
I lost my dad to leukemia 20 years ago, fundraising all year in his honor for the year he knew about his diagnosis but didn’t tell anyone. We also lost his mom (grandma) to leukemia in 2002 and my mother-in-law in 2007 to leukemia. I proudly support The Leukemia & Lymphoma Society (LLS) and try to donate every year, but this year, I hope to donate a big chunk to help current patients and their families.
Pam
Pam Katten died on September 24, 2002 after a year-long battle with acute myeloid leukemia (AML).
Treatment
It's important that your doctor is experienced in treating patients with hairy cell leukemia or works in consultation with a hairy cell leukemia specialist. This type of specialist is usually called a hematologist oncologist.
Types of Hairy Cell Leukemia TreatmentFor many people with hairy cell leukemia, starting treatment helps them focus on moving ahead and looking forward to their disease's remission.
Several types of approaches and treatment are used for adults with hairy cell leukemia, some at different stages:
Clinical Trials
Taking part in a clinical trial may be a treatment choice for some hairy cell leukemia patients. Clinical trials are under way to develop treatments that increase the remission rate of hairy cell leukemia or cure the disease. Today's standard treatments for cancer are based on earlier clinical trials. The Leukemia & Lymphoma Society continues to invest funds in hairy cell leukemia research.
Doug
In July 2014, my defibrillator fired while I was at a diner. Upon testing at the hospital I found out I have acute promyelocytic leukemia (APL). Much to my surprise, it was discovered by a simple blood test.
Relapsed and Refractory
Some patients' cancer returns after a successful course of treatment. This is called a relapse.
Some patients' cancer does not respond to treatment. This is called refractory chronic myelomonocytic leukemia (CMML).
If you have relapsed or refractory CMML, talk with your doctor about whether taking part in a clinical trial may be a good option for you.
Matthew
Our Matthew was first diagnosed with acute lymphoblastic leukemia (ALL) in August 2015 at the age of 12. He relapsed with ALL in December 2016 and underwent his first bone marrow transplant in February 2017 with marrow from an anonymous male donor from New Jersey.
In January 2019, he was diagnosed with mixed phenotype acute leukemia (MPAL). He underwent his second bone marrow transplant in February 2019 with marrow from his first donor's twin brother. Our two families have become very close since we were able to meet after the first transplant.
Childhood and Adolescent Blood Cancer Facts and Statistics
Childhood and Adolescent Blood Cancers- An estimated 54,868 children and adolescents younger than 20 years in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs).
- Leukemia is the most common cancer diagnosed in children and adolescents younger than 20 years and accounts for 25.4 percent of all cancer cases in this age-group.
- From 2016 to 2020, the most recent 5 years for which data are available, leukemia and lymphoma accounted for 38.4 percent of all cancer types in
Mateo
Our Journey On June 26 2013, at six years old, Mateo was diagnosed with acute lymphoblastic leukemia (ALL). Our world was completely upside down since that night. Our hearts shattered when we processed the words "your child has cancer ".
Relapsed and Refractory
Some patients still have leukemia cells in their bone marrow after hairy cell leukemia treatment. This is called refractory leukemia. Some patients have a return of leukemia cells in the marrow and a decrease in normal blood cells after remission. This is called a relapse.
Drug therapy that can be used to treat relapsed or refractory HCL includes:
Childhood AML
Childhood Acute Myeloid Leukemia (AML)Because of new and better therapies, cancer survival rates for children with acute myeloid leukemia (AML) have improved dramatically during the last several decades. Scientists continue to search for the causes of childhood leukemia so they can develop better treatments with less toxic side effects.
Find statistics for Childhood AML and other blood cancers.
Giulia Casorati, Ph.D.
A Leading Researcher Advancing Immunotherapy for Acute Myeloid Leukemia
In Italy, Dr. Giulia Casorati is focused on adoptive cell immunotherapy to treat patients with acute myeloid leukemia (AML). Immunotherapy is a groundbreaking approach to treatment that involves harnessing the power of the patient’s own immune system to kill cancer. She is developing an immunotherapy approach that engineers T cells to specifically target CD1, a molecule found on the surface of AML cells.
Diagnosis
Diagnosing acute lymphoblastic leukemia (ALL) and the ALL subtype usually involves a series of tests. An accurate diagnosis of the subtype is important. The exact diagnosis helps the doctor
- Estimate how the disease will progress
- Determine the appropriate treatment
In children, a diagnosis of ALL generally requires a finding that 25 percent or more of the cells in the bone marrow are leukemic blasts of lymphoid origin (lymphoblasts).
Clinical Trials
Taking part in a clinical trial may be a good treatment choice for people with chronic myelomonocytic leukemia (CMML). Clinical trials are under way to help improve treatment, extend survival and improve the quality of life for CMML patients. Today's standard treatments for cancer are based on earlier clinical trials. The Leukemia & Lymphoma Society continues to invest funds in CMML research.